www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

Comprehensive BRCA gene analysis

The BRCA Pro Panel offers a comprehensive genetic test that detects BRCA1/2 mutations and variants that could predispose individuals to breast and ovarian cancer. It supports early diagnosis and genetic counselling by identifying individuals who are at high risk, allowing for better preventive measures and more tailored treatment strategies. The panel helps clinicians provide personalised care for patients, offering options like preventive surgeries, chemoprevention, or targeted therapies based on the genetic findings.

BRCA panel highlights

Benefits of the AmoyDx BRCA Pro Panel

  • Comprehensive BRCA1/2 mutation detection - identifies SNVs, indels, and large rearrangements (LRs) across all coding regions, intron/exon boundaries, and select UTRs for high-precision variant analysis
  • Supports hereditary and somatic cancer risk assessment - detects both germline and somatic mutations in breast, ovarian, prostate, pancreatic, and melanoma cancers, aiding in early diagnosis and targeted therapy decisions
  • High sensitivity and accuracy - leverages AmoyDx HANDLE® technology with unique molecular indexes (UMIs) to eliminate sequencing bias and improve variant detection reliability
  • Fast and cost-effective workflow – NGS library preparation in under 5 hours, with only 1 hour of hands-on time, making it a time-saving, decentralised solution for laboratories
  • Secure and streamlined data analysis - integrates seamlessly with AmoyDx NGS Data Analysis System (ANDAS) for automated, secure, and intuitive mutation analysis while ensuring data protection and regulatory compliance

Applications of the AmoyDx BRCA Pro Panel

  • Detection of BRCA1/2 germline and somatic mutations
  • Risk assessment for hereditary breast, ovarian, prostate, and pancreatic cancers
  • Determining eligibility for PARP inhibitors (PARPi) and other targeted therapies
  • Clinical decision-making for cancer prevention and treatment
  • Genetic screening in oncology and molecular pathology labs

Specifications

Target regions All coding regions of BRCA1/2 genes, exon-intron boundaries, some introns and UTRs
Alterations detected SNVs & InDels (somatic/germline), LRs (germline)
Sample type DNA from FFPE tissue, whole blood
DNA input Optimal 50ng (minimum 30ng)
Data output per sample 0.06 Gb for germline variants, 0.3 Gb for somatic variants
Sequencing type PE150
Sequencer Illumina MiSeqDx, NextSeq 500, NextSeq 550Dx
TAT for library preparation 5 hours (<1 hour hands-on time)
TAT from sample to report 3 days

Materials for download

AmoyDx BRCA Pro Panel user manual

Products

Note: product availability depends on country - see product detail page.

Details Cat number & supplier Size Price
BRCA Pro Panel 8.06.0104 · Amoy Diagnostics
8.06.0104
Amoy Diagnostics
24 tests £4542.00
24 tests
view
BRCA Pro Panel 8.06.0117 · Amoy Diagnostics
8.06.0117
Amoy Diagnostics
24 tests £4542.00
24 tests
view